$4.07 Million in Sales Expected for Kadmon Holdings, Inc. (KDMN) This Quarter
Brokerages expect Kadmon Holdings, Inc. (NYSE:KDMN) to post sales of $4.07 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Kadmon Holdings’ earnings. The lowest sales estimate is $3.00 million and the highest is $5.13 million. Kadmon Holdings reported sales of $4.28 million during the same quarter last year, which would suggest a negative year-over-year growth rate of 4.9%. The firm is scheduled to announce its next earnings results on Wednesday, March 28th.
According to Zacks, analysts expect that Kadmon Holdings will report full-year sales of $4.07 million for the current year, with estimates ranging from $13.80 million to $15.73 million. For the next year, analysts expect that the company will post sales of $11.78 million per share, with estimates ranging from $4.65 million to $18.90 million. Zacks’ sales calculations are an average based on a survey of research firms that cover Kadmon Holdings.
Kadmon Holdings (NYSE:KDMN) last issued its quarterly earnings results on Thursday, November 9th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.04). The company had revenue of $2.28 million for the quarter, compared to the consensus estimate of $5.69 million. The company’s revenue was down 60.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($4.24) EPS.
In other Kadmon Holdings news, major shareholder Goldentree Asset Management Lp sold 302,950 shares of the company’s stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $2.73, for a total value of $827,053.50. The sale was disclosed in a filing with the SEC, which is available through this link. 8.41% of the stock is owned by corporate insiders.
A number of hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Kadmon Holdings by 166.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,508,869 shares of the company’s stock worth $5,870,000 after acquiring an additional 941,549 shares in the last quarter. Sphera Funds Management LTD. bought a new position in shares of Kadmon Holdings during the third quarter valued at approximately $3,685,000. Crestline Management LP bought a new position in shares of Kadmon Holdings during the third quarter valued at approximately $2,011,000. Sabby Management LLC bought a new position in shares of Kadmon Holdings during the second quarter valued at approximately $2,112,000. Finally, Susquehanna International Group LLP boosted its stake in shares of Kadmon Holdings by 3,211.2% during the third quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after purchasing an additional 429,752 shares in the last quarter. Institutional investors and hedge funds own 27.96% of the company’s stock.
Shares of Kadmon Holdings (NYSE KDMN) traded down $0.07 during trading hours on Thursday, reaching $3.52. 267,700 shares of the company traded hands, compared to its average volume of 281,517. Kadmon Holdings has a one year low of $2.05 and a one year high of $5.93.
COPYRIGHT VIOLATION WARNING: “$4.07 Million in Sales Expected for Kadmon Holdings, Inc. (KDMN) This Quarter” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/11/23/4-07-million-in-sales-expected-for-kadmon-holdings-inc-kdmn-this-quarter.html.
Kadmon Holdings Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.